{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006793","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.632092+00:00","generated_at":"2026-06-02T21:47:30.360621+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"GlycoMimetics' pivotal Phase 3 trial of uproleselan in R/R AML fails to meet primary endpoint of overall survival","bullets":["Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.","Median overall survival 13 months (uproleselan) vs 12.3 months (placebo).","NCI Phase 2/3 study in newly diagnosed AML remains ongoing; company will submit data to medical meeting.","Cash and cash equivalents $31.3M as of March 31, 2024, down from $41.8M at Dec 31, 2023.","Q1 2024 R&D expenses $6.0M, G&A $5.1M; shares outstanding 64.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006793","json":"https://secwatch.observer/filing/0001558370-24-006793.json","markdown":"https://secwatch.observer/filing/0001558370-24-006793.md","text":"https://secwatch.observer/filing/0001558370-24-006793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/glyc-20240506x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:47:30.360621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"771dbb4e3ed78ea50d2af0b7d849be415e34490a","claim":"CRESCENT BIOPHARMA, INC. reported preliminary financial results for first quarter of 2024.","evidence_excerpt":"On May 6, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing, in addition to the information described in Item 7.01 below, its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}